Repositioning of new potential schistosomicidal drugs using chemogenomic strategy
نویسندگان
چکیده
Background Schistosomiasis remains a severe problem of public health in developing countries [1]. Several reports show that praziquantel, the drug of choice for treating schistosomiasis, can select Schistosoma mansoni strains resistant to the drug. Thus, developing new drugs against this parasitosis is a highly desirable goal [2]. In this context, enzymes involved in energetic metabolism could represent attractive drug targets for novel anti-schistosome chemotherapies [3,4]. We report a chemogenomic strategy for identification of approved drugs that may be able to interfere with energetic metabolism of the Schistosoma mansoni.
منابع مشابه
Correction: In Silico Repositioning-Chemogenomics Strategy Identifies New Drugs with Potential Activity against Multiple Life Stages of Schistosoma mansoni
Morbidity and mortality caused by schistosomiasis are serious public health problems in developing countries. Because praziquantel is the only drug in therapeutic use, the risk of drug resistance is a concern. In the search for new schistosomicidal drugs, we performed a target-based chemogenomics screen of a dataset of 2,114 proteins to identify drugs that are approved for clinical use in human...
متن کاملDrug target prediction using adverse event report systems: a pharmacogenomic approach
MOTIVATION Unexpected drug activities derived from off-targets are usually undesired and harmful; however, they can occasionally be beneficial for different therapeutic indications. There are many uncharacterized drugs whose target proteins (including the primary target and off-targets) remain unknown. The identification of all potential drug targets has become an important issue in drug reposi...
متن کاملRecent therapeutic approaches in control of parasitic diseases with special reference to schistosomiasis
Control of schistosomiasis relies on a single drug, praziquantel (PZQ). Given the rising concerns about the potential emergence of PZQ-resistant strains, it has now become necessary to search for novel therapeutics. Efforts have been made for developing new schistosomicidal drugs, or testing existing drugs originally used for non-related diseases. However, the current pace for antischistosomal ...
متن کاملA structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase
Valosin-containing protein (VCP/p97) ATPase (a.k.a. Cdc48) is a key member of the ER-associated protein degradation (ERAD) pathway. ERAD and VCP/p97 have been implicated in a multitude of human diseases, such as neurodegenerative diseases and cancer. Inhibition of VCP/p97 induces proteotoxic ER stress and cell death in cancer cells, making it an attractive target for cancer treatment. However, ...
متن کاملIn silico drug repositioning: what we need to know.
Drug repositioning, exemplified by sildenafil and thalidomide, is a promising way to explore alternative indications for existing drugs. Recent research has shown that bioinformatics-based approaches have the potential to offer systematic insights into the complex relationships among drugs, targets and diseases necessary for successful repositioning. In this article, we propose the key bioinfor...
متن کامل